Valneva Se (VALN)
NASDAQ:VALN
Want to see VALN full AI Analyst Report?
VALN Stock Chart & Stats
$5.96
$0.03(0.64%)
At close: 4:00 PM EST
$5.96
$0.03(0.64%)
Day’s Range― - ―
52-Week Range$5.06 - $12.25
Previous CloseN/A
Volume18.63K
Average Volume (3M)35.88K
Market Cap
$501.37M
Enterprise Value$545.93M
Total Cash (Recent Filing)$105.37M
Total Debt (Recent Filing)$209.72M
Price to Earnings (P/E)―
Beta1.12
Next Earnings
Aug 13, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.63
Shares Outstanding94,885,620
10 Day Avg. Volume19,231
30 Day Avg. Volume35,882
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)5.95
Price to Sales (P/S)3.61
P/FCF Ratio-11.00
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue3.49
Enterprise Value/Gross Profit11.85
Enterprise Value/Ebitda-6.06
Forecast
1Y Price Target
$12.23Price Target Upside105.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.89
Revenue Forecast (FY)$179.74M
Bulls Say, Bears Say
Bulls Say
Late-stage Pipeline: Lyme VaccineA >70% Phase III efficacy readout for the Pfizer-partnered Lyme candidate is a durable, transformative asset if approved. Partnership with Pfizer strengthens regulatory and commercialization execution, could unlock milestone and royalty streams, and materially diversify revenues beyond travel vaccines.
Established Commercial Vaccine FranchiseA multi-product commercial portfolio provides recurring product sales and customer relationships across travel and public-health channels. This franchise underpins cash generation and market access, supports distribution partnerships and provides a platform to scale new vaccine launches over the medium term.
Manufacturing And Field Execution With PartnersDemonstrated ability to run large partner-led campaigns and secure local licensure shows operational execution and partner credibility. Local manufacturing and pilot rollouts reduce time-to-market in key regions, validate commercial demand, and strengthen go-to-market and supply capabilities long term.
Bears Say
Persistent Negative Cash GenerationConsistent negative operating and free cash flow forces reliance on external financing and dilutive raises, constrains reinvestment in commercial expansion and R&D, and shortens runway absent sustained margin or revenue improvement, raising medium-term survival and execution risk.
Deteriorating Balance Sheet And Rising LeverageSharply higher leverage reduces financial flexibility and increases interest and refinancing risk while equity has declined. With continued losses, the company has less cushion to absorb setbacks, limiting strategic options and increasing the probability of future financing under stressed terms.
Manufacturing/regulatory Constraints Raising CostsRegulatory remediation and failed-batch costs at Almeida are structural headwinds: higher COGS, inventory provisions and idle costs compress margins and delay scalable U.S. supply. The need for remediation prolongs elevated costs and reduces near- to mid-term commercial upside from manufacturing scale.
Valneva News
VALN FAQ
What was Valneva Se’s price range in the past 12 months?
Valneva Se lowest stock price was $5.06 and its highest was $12.25 in the past 12 months.
What is Valneva Se’s market cap?
Valneva Se’s market cap is $501.37M.
When is Valneva Se’s upcoming earnings report date?
Valneva Se’s upcoming earnings report date is Aug 13, 2026 which is in 53 days.
How were Valneva Se’s earnings last quarter?
Valneva Se released its earnings results on May 13, 2026. The company reported -$0.422 earnings per share for the quarter, missing the consensus estimate of -$0.148 by -$0.274.
Is Valneva Se overvalued?
According to Wall Street analysts Valneva Se’s price is currently Undervalued.
Does Valneva Se pay dividends?
Valneva Se does not currently pay dividends.
What is Valneva Se’s EPS estimate?
Valneva Se’s EPS estimate is -0.19.
How many shares outstanding does Valneva Se have?
Valneva Se has 94,885,620 shares outstanding.
What happened to Valneva Se’s price movement after its last earnings report?
Valneva Se reported an EPS of -$0.422 in its last earnings report, missing expectations of -$0.148. Following the earnings report the stock price went down -2.167%.
Which hedge fund is a major shareholder of Valneva Se?
Currently, no hedge funds are holding shares in VALN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Valneva Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.23 (105.12% Upside)
$12.23 (105.12% Upside)
Blogger Sentiment
Neutral
VALN Sentiment 50%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.94%
12-Months-Change
Fundamentals
Return on Equity
-106.22%
Trailing 12-Months
Asset Growth
-17.72%
Trailing 12-Months
Company Description
Valneva Se
Valneva SE operates as a specialized biopharmaceutical company, concentrating its efforts on developing and bringing to market preventative vaccines for infectious diseases where current medical options are insufficient. Its portfolio of commercial travel vaccines includes IXIARO, an inactivated vaccine derived from Vero cell culture, which provides active immunity against Japanese encephalitis. Another offering is DUKORAL, an oral vaccine designed to guard against diarrhea induced by Vibrio cholerae or enterotoxigenic Escherichia coli (ETEC) bacteria. The company's development pipeline features VLA2001, a candidate vaccine targeting SARS-CoV-2. Additionally, Valneva is progressing with VLA15, a Lyme disease vaccine candidate that has successfully concluded Phase II clinical trials and is being co-developed and commercialized with Pfizer, Inc. They are also advancing VLA1553, a chikungunya virus vaccine candidate currently undergoing Phase III clinical evaluation, in partnership with Instituto Butantan for its development, production, and marketing as a single-shot vaccine. Valneva's products are sold across a wide geographical area, including the United States, Canada, Germany, Austria, the Nordic countries, the United Kingdom, various other European nations, and internationally. Founded in 1998, the company maintains its headquarters in Saint-Herblain, France.
VALN Company Deck
VALN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed picture: strong R&D and clinical achievements (notably a clinically meaningful Lyme Phase III efficacy result with planned regulatory submissions, progress on Chikungunya and Shigella, and a solid cash buffer) are offset by pronounced near-term financial weakness (sharp revenue declines, margin compression, higher COGS from manufacturing transfer, widened net loss), a guidance downgrade tied to travel headwinds, and ongoing manufacturing/regulatory remediation at the Almeida site. Management is pursuing aggressive cost reductions and is positioning for a potential transformative regulatory outcome for Lyme, but near-term operational and financial challenges remain significant.View all VALN earnings summariesVALN Stock 12 Month Forecast
Average Price Target
$12.23
▲(105.12% Upside)
Technical Analysis
Arbutus Biopharma
―
Urogen Pharma
―
Inventiva
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Ownership Overview
―
Insiders
0.13% Mutual Funds
3.96% Other Institutional Investors
95.91% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---